SANUWAVE (SNWV)
Builds non-contact ultrasound systems and applicators for wound care.
$4.44
At close−0.16 (−3.48%)
In millions of USD, except per-share figures
| In millions | Q3 FY23Sep 2023 | Q4 FY23Dec 2023 | Q1 FY24Mar 2024 | Q2 FY24Jun 2024 | Q3 FY24Sep 2024 | Q4 FY24Dec 2024 | Q1 FY25Mar 2025 | Q2 FY25Jun 2025 | Q3 FY25Sep 2025 | Q4 FY25Dec 2025 | Q1 FY26Mar 2026 | Q2 FY26Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 5 | 7 | 6 | 7 | 9 | 10 | 9 | 10 | 11 | 13 | 10 | 10 |
| Cost of revenue | 1 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 3 | 3 | 2 | 2 |
| Gross profit | 4 | 5 | 4 | 5 | 7 | 8 | 7 | 8 | 9 | 10 | 7 | 7 |
| 4 | 4 | 5 | 3 | 5 | 6 | 6 | 6 | 7 | 9 | 8 | 8 | |
| Research & development | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 1 |
| 4 | 3 | 5 | 3 | 5 | 5 | 6 | 6 | 7 | 8 | 8 | 7 | |
| Selling & marketing | 1 | 1 | 1 | 1 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 |
| General & administrative | 3 | 2 | 4 | 2 | 3 | 3 | 4 | 4 | 5 | 6 | 5 | 5 |
| Other expenses | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Operating income | −1 | 1 | −1 | 2 | 2 | 3 | 1 | 2 | 1 | 1 | −1 | 0 |
| −23 | 17 | −3 | 5 | −23 | −15 | −7 | −1 | 9 | 6 | 0 | 0 | |
| Interest expense | 4 | 3 | 4 | 4 | 4 | 3 | 2 | 2 | 2 | 1 | 1 | 1 |
| Other non-operating income | 19 | −20 | 0 | −8 | 19 | 13 | 5 | −1 | −11 | −6 | 0 | 0 |
| Income before tax | −24 | 18 | −5 | 7 | −21 | −13 | −6 | 1 | 10 | 6 | −1 | −1 |
| Income tax expense | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net income from continuing operations | −24 | 18 | −5 | 7 | −21 | −13 | −6 | 1 | 10 | 6 | −1 | −1 |
| Net income | −24 | 18 | −5 | 7 | −21 | −13 | −6 | 1 | 10 | 6 | −1 | −1 |
| EPS, basic | −$9.95 | $6.00 | −$1.46 | $2.08 | −$6.49 | −$3.33 | −$0.66 | $0.01 | $1.21 | $0.71 | −$0.17 | −$0.08 |
| EPS, diluted | −$9.95 | $6.00 | −$1.46 | $1.77 | −$6.49 | −$3.33 | −$0.66 | $0.01 | $1.13 | $0.02 | −$0.17 | −$0.08 |
| Weighted average shares, basic | 2 | 3 | 3 | 3 | 3 | 4 | 9 | 9 | 9 | 9 | 9 | 9 |
| Weighted average shares, diluted | 2 | 3 | 3 | 4 | 3 | 4 | 9 | 9 | 9 | 9 | 9 | 9 |
| EBITDA | −20 | 22 | −1 | 11 | −17 | −10 | −4 | 3 | 12 | 8 | −1 | 0 |
| Depreciation & amortization | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 |
| EBIT | −20 | 21 | −1 | 10 | −17 | −10 | −4 | 3 | 12 | 7 | −1 | 0 |